Mr. Thomas O'Shaughnessy reports

ONCO-INNOVATIONS INITIATES ADME STUDIES SUPPORTING DEVELOPMENT OF ONC010

Further to the news release dated May 8, 2026, Onco-Innovations Ltd. has initiated key absorption, distribution, metabolism and excretion studies for ONC010, the company's lead nanoparticle-formulated polynucleotide kinase phosphatase inhibitor. The studies are designed to characterize ONC010's pharmacokinetic and metabolic profile and support the continued IND-enabling development of the program.

The initial ADME work is focused on metabolism of the active pharmaceutical ingredient in the ONC010 lead drug candidate. These data are intended to support the company's broader development strategy by informing manufacturing activities, formulation optimization, toxicology studies and future clinical translation. The studies are expected to contribute to the growing body of preclinical evidence supporting the continued advancement of ONC010 toward clinical evaluation.

"Initiating these ADME studies represents another important step in our systematic advancement of ONC010. A thorough understanding of how a therapeutic candidate is absorbed, distributed, metabolized and eliminated is fundamental to successful drug development," said Thomas O'Shaughnessy, chief executive officer of Onco-Innovations.

The ADME studies form part of Onco-Innovations' broader IND-enabling development program for ONC010, which also includes manufacturing, formulation, safety and regulatory activities intended to support future clinical evaluation.

"ADME studies play a critical role in evaluating the clinical potential of an investigational oncology therapy. The data generated through this program are expected to provide valuable information to support dose selection, safety assessment and overall development planning. These studies will further strengthen the scientific foundation of the ONC010 program as we continue progressing toward clinical translation," said Dr. Islam Mohamed, chief medical officer of Onco-Innovations.

About Onco-Innovations Ltd.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide licence to patented technology that targets solid tumours.

We seek Safe Harbor.